— Research monograph
Tesamorelin
A stabilized growth-hormone-releasing-hormone analog studied for visceral adiposity.
Updated
- Class
- Stabilized GHRH(1-44) analog with trans-3-hexenoic acid N-terminal modification
- Half-life (research)
- ~25–40 min (subcutaneous administration in clinical studies).
- Origin
- Developed by Theratechnologies. Approved by the FDA in 2010 (brand name Egrifta) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy — one of the few approved peptide therapeutics in this class.
- Solubility
- Physicochemical context only. Merit Sciences publishes no reconstitution or preparation procedures.
What is Tesamorelin?
Tesamorelin is a synthetic 44-amino-acid analog of human GHRH carrying a trans-3-hexenoic acid moiety at the N-terminus. This modification stabilizes the peptide against dipeptidyl peptidase IV (DPP-IV) cleavage, substantially extending plasma half-life relative to native GHRH and to sermorelin.
The compound is the most clinically validated GHRH analog in research literature, having been studied in multiple multicenter randomized trials in HIV-associated lipodystrophy and, more recently, NAFLD.
How does Tesamorelin work?
Selective agonist at pituitary GHRH receptors. The trans-hexenoic acid modification confers DPP-IV resistance, producing longer duration of GHRH-receptor activation per dose. Downstream effects are mediated by pulsatile GH release and consequent IGF-1 generation.
Research applications
- GHRH receptor pharmacology
- HIV-lipodystrophy research
- Hepatic steatosis investigation
- Visceral adipose tissue studies
Tesamorelin at Merit
- Tesamorelin 10 mgCurrent certificate: July 2026 batch, 99.01% purity
- Tesamorelin 20 mgCurrent certificate: July 2026 batch, 99.46% purity
Research review on The Assay, Merit’s editorial publication: Tesamorelin vs Sermorelin: One Approved, One Discontinued
Form & storage
Tesamorelin ships as a sealed, lyophilized (freeze-dried) powder. Physicochemical context only. Merit Sciences publishes no reconstitution or preparation procedures. Store sealed, light-protected, and follow your institution’s handling procedures for research materials.
Frequently asked questions
What is Tesamorelin?
Tesamorelin is a synthetic 44-amino-acid analog of human GHRH carrying a trans-3-hexenoic acid moiety at the N-terminus. This modification stabilizes the peptide against dipeptidyl peptidase IV (DPP-IV) cleavage, substantially extending plasma half-life relative to native GHRH and to sermorelin. Merit supplies it as a lyophilized research compound for research use only, not for human or veterinary use.
How does Tesamorelin work?
Selective agonist at pituitary GHRH receptors. The trans-hexenoic acid modification confers DPP-IV resistance, producing longer duration of GHRH-receptor activation per dose. Downstream effects are mediated by pulsatile GH release and consequent IGF-1 generation. Mechanistic descriptions summarize published preclinical findings and are not clinical claims.
What is the half-life of Tesamorelin?
~25–40 min (subcutaneous administration in clinical studies). Values reflect preclinical or research-context reports, not clinical pharmacokinetics.
Is Merit Tesamorelin for human use?
No. It is sold strictly for research use only: not for human or veterinary use, and not for diagnostic or therapeutic use.
Is Tesamorelin FDA-approved?
Tesamorelin is FDA-approved only as specific branded prescription drug products; research material sold as tesamorelin is not one of those products and is not FDA-approved. Supplied for research use only. Tesamorelin is named on the WADA 2026 Prohibited List under S2 as a growth hormone releasing hormone analogue and is prohibited at all times.
How is each batch of Tesamorelin tested?
Every Merit batch is tested by an independent laboratory for identity and HPLC purity before it is listed, and Merit identifies batches by date rather than by lot number. Current certificates: Tesamorelin 10 mg, July 2026 batch, 99.01% purity (meritsciences.com/coa/COA-2026-ETCHHO); Tesamorelin 20 mg, July 2026 batch, 99.46% purity (meritsciences.com/coa/COA-2026-O4M8J4).
Regulatory status checked October 22, 2026 against: Drugs@FDA, WADA Prohibited List.
References
- Metabolic effects of a growth hormone-releasing factor in patients with HIV. Falutz J, Allas S, Blot K, et al.. New England Journal of Medicine, 2007 · PMID 18057338
- Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Stanley TL, Fourman LT, Feldpausch MN, et al.. The Lancet HIV, 2019 · PMID 31611038
- Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Stanley TL, Falutz J, Marsolais C, et al.. Clinical Infectious Diseases, 2012 · PMID 22495074
For research use only. Not for human or veterinary use. Reference information summarized from published literature, not medical advice.